clevercast
{"PEE04":{"id":"2M46na","strictid":"PEE04","name":"PEEK04 LIVE","description":"","account_id":"WxRD9M","ts":1607511600},"WEB04":{"id":"VDx0rX","strictid":"WEB04","name":"WEB04","description":"","account_id":"WxRD9M","ts":1607493600},"WEB03":{"id":"W9bamb","strictid":"WEB03","name":"WEB03","description":"","account_id":"WxRD9M","ts":1607407200},"WEB02":{"id":"Vv8ZyL","strictid":"WEB02","name":"WEB02","description":"","account_id":"WxRD9M","ts":1607320800},"WEB01":{"id":"Ww4n4n","strictid":"WEB01","name":"WEB01","description":"","account_id":"WxRD9M","ts":1607234400},"CLO01":{"id":"AG1BLq","strictid":"CLO01","name":"CLO01 LIVE","description":"Live Closing Ceremony\n","account_id":"WxRD9M","ts":1607533200},"LBR01":{"id":"ARXRzM","strictid":"LBR01","name":"LBR01 LIVE","description":"Live Late Breakers","account_id":"WxRD9M","ts":1607526000},"SCS08":{"id":"WdEw0P","strictid":"SCS08","name":"SCS08","description":"Co-infections in influenza, RSV disease and COVID-19","account_id":"WxRD9M","ts":1607518800},"SPI07":{"id":"A0wZ9y","strictid":"SPI07","name":"SPI07","description":"Burden of influenza, RSV disease and COVID-19 and impact on society","account_id":"WxRD9M","ts":1607518800},"SPI06":{"id":"WN4qrz","strictid":"SPI06","name":"SPI06","description":"Risk evaluation and communication strategies in influenza and COVID-19: lessons learned","account_id":"WxRD9M","ts":1607518800},"KEY08":{"id":"WEzP46","strictid":"KEY08","name":"KEY08","description":"Heidi Larsson","account_id":"WxRD9M","ts":1607518800},"KEY05":{"id":"WXwL5Z","strictid":"KEY05","name":"KEY05","description":"Neil Ferguson","account_id":"WxRD9M","ts":1607511600},"SCS12":{"id":"WgNYdo","strictid":"SCS12","name":"SCS12","description":"Animal influenza, ecology and epidemiology ","account_id":"WxRD9M","ts":1607511600},"SCS13":{"id":"258rEm","strictid":"SCS13","name":"SCS13","description":"Influenza, RSV disease and COVID-19 vaccination: current and future approaches ","account_id":"WxRD9M","ts":1607511600},"SAT05":{"id":"VeB17z","strictid":"SAT05","name":"SAT05 LIVE","description":" 05 LIVE ESPID\/ESWI supported by AZ","account_id":"WxRD9M","ts":1607504400},"GOM03":{"id":"21Olvv","strictid":"GOM03","name":"GOMO03 LIVE","description":"Goodmorning COLLIN","account_id":"WxRD9M","ts":1607500800},"MOR03":{"id":"Vr9bL3","strictid":"MOR03","name":"MORWEL03","description":"Morning welcome lecture ROCHE","account_id":"WxRD9M","ts":1607497200},"MEE02":{"id":"AZwZe5","strictid":"MEE02","name":"MEET02 + RECAP 3 LIVE","description":"Meet Collin and Marco live","account_id":"WxRD9M","ts":1607454000},"SAT06":{"id":"Wj19y6","strictid":"SAT06","name":"SAT06 LIVE","description":"Satellite Sanofi Pasteur","account_id":"WxRD9M","ts":1607446800},"SAT04":{"id":"24M69N","strictid":"SAT04","name":"SAT04 LIVE","description":"Satellite Roche","account_id":"WxRD9M","ts":1607439600},"KEY09":{"id":"2OLdM6","strictid":"KEY09","name":"KEY09","description":"Janina Krambach\n","account_id":"WxRD9M","ts":1607432400},"PEE03":{"id":"AkLxkJ","strictid":"PEE03","name":"PEEK03 LIVE","description":"","account_id":"WxRD9M","ts":1607432400},"SCS11":{"id":"Wq1BQ3","strictid":"SCS11","name":"SCS11","description":"Antiviral and immune therapy for influenza, RSV disease and COVID-19 ","account_id":"WxRD9M","ts":1607432400},"SCS10":{"id":"27EaP5","strictid":"SCS10","name":"SCS10","description":"Influenza, RSV disease and COVID-19 vaccination: current and future approaches ","account_id":"WxRD9M","ts":1607432400},"SCS09":{"id":"2bY8bw","strictid":"SCS09","name":"SCS09","description":"Threats and risk management of epidemics and pandemics ","account_id":"WxRD9M","ts":1607432400},"SAT08":{"id":"VPry6L","strictid":"SAT08","name":"SAT08 LIVE","description":" bioNtech Lunch symposium","account_id":"WxRD9M","ts":1607425200},"KEY04":{"id":"Wq1BQ1","strictid":"KEY04","name":"KEY04","description":"Melanie Saville","account_id":"WxRD9M","ts":1607425200},"SCS07":{"id":"27EaP3","strictid":"SCS07","name":"SCS07","description":"Influenza, RSV disease and COVID-19: clinical impact and diagnostic approaches (including disease management in primary healthcare and hospital settings)\n","account_id":"WxRD9M","ts":1607418000},"YSS01":{"id":"2bY8LM","strictid":"YSS01","name":"YSS01 LIVE","description":"Young Scientists at work LIVE","account_id":"WxRD9M","ts":1607418000},"GOM02":{"id":"VPryE6","strictid":"GOM02","name":"GOMO02 LIVE","description":"Goodmoring 2 with COLLIN","account_id":"WxRD9M","ts":1607414400},"MOR02":{"id":"Wx8qBy","strictid":"MOR02","name":"MORWEL02","description":"Morning Welcome Lecture Roche","account_id":"WxRD9M","ts":1607410800},"REC02":{"id":"VeB1l4","strictid":"REC02","name":"RECAP02 LIVE","description":"Recap of the day 07\/12\/2020\n","account_id":"WxRD9M","ts":1607369400},"MEE01":{"id":"21OlqM","strictid":"MEE01","name":"MEET01 LIVE","description":"Meet Collin and Ab 07\/12\/2020","account_id":"WxRD9M","ts":1607360400},"COM03":{"id":"Ww4KEx","strictid":"COM03","name":"COM03","description":"Company Lecture Keynote Cidara","account_id":"WxRD9M","ts":1607360400},"SCS06":{"id":"2a0aQy","strictid":"SCS06","name":"SCS06","description":"Innate and adaptive immune responses towards influenza, RSV disease and COVID-19 ","account_id":"WxRD9M","ts":1607360400},"SPI05":{"id":"A6PpOv","strictid":"SPI05","name":"SPI05","description":"Influenza, RSV disease and COVID-19 from a global health perspective, including underserved communities ","account_id":"WxRD9M","ts":1607360400},"SCS05":{"id":"2nyJwZ","strictid":"SCS05","name":"SCS05 LIVE","description":"Reservoirs for future pandemics LIVE ","account_id":"WxRD9M","ts":1607353200},"KEY03":{"id":"Wj19pg","strictid":"KEY03","name":"KEY03","description":"David Baauer","account_id":"WxRD9M","ts":1607353200},"SPI04":{"id":"24M6k4","strictid":"SPI04","name":"SPI04","description":"Influenza, RSV disease and COVID-19 intervention strategies: current practice and future strategies","account_id":"WxRD9M","ts":1607353200},"SCS04":{"id":"2OLdPK","strictid":"SCS04","name":"SCS04","description":"Viral and host factors in the pathogenesis of influenza, RSV disease and COVID-19 including genomics and big data ","account_id":"WxRD9M","ts":1607353200},"SAT03":{"id":"Vy8dbw","strictid":"SAT03","name":"SAT03 LIVE","description":"Live Satellite Janssen","account_id":"WxRD9M","ts":1607346000},"PEE02":{"id":"AK47ex","strictid":"PEE02","name":"PEEK02 LIVE","description":"","account_id":"WxRD9M","ts":1607338800},"COM02":{"id":"V3nMyY","strictid":"COM02","name":"COM02","description":"Company Lecture Janssen 2","account_id":"WxRD9M","ts":1607338800},"KEY02":{"id":"VBkg1g","strictid":"KEY02","name":"KEY02","description":"Johan Neyts","account_id":"WxRD9M","ts":1607338800},"SPI03":{"id":"VYZj4d","strictid":"SPI03","name":"SPI03","description":"why are influenza and RSV a priority for policy makers and what can learn from COVID-19 ","account_id":"WxRD9M","ts":1607338800},"SAT02":{"id":"VDxJvL","strictid":"SAT02","name":"SAT02 LIVE","description":"Influenza in persons living with diabetes. Pathogenesis and prevention","account_id":"WxRD9M","ts":1607331600},"GOM01":{"id":"W9bzne","strictid":"GOM01","name":"GOMO01 LIVE","description":"Goodmorning Coffee with Collin Russel","account_id":"WxRD9M","ts":1607328000},"MOR01":{"id":"WmdD95","strictid":"MOR01","name":"MORWEL01","description":"Morning Welcome 07\/12\/2020","account_id":"WxRD9M","ts":1607324400},"REC01":{"id":"VzXyk3","strictid":"REC01","name":"RECAP01","description":"Recap of the day 06\/12\/2020","account_id":"WxRD9M","ts":1607288400},"SAT07":{"id":"ApjEB0","strictid":"SAT07","name":"SAT07","description":"Astra Zeneca","account_id":"WxRD9M","ts":1607281200},"COM01":{"id":"2M4K31","strictid":"COM01","name":"COM01","description":"Company Lecture Janssen","account_id":"WxRD9M","ts":1607274000},"SCS03":{"id":"AZwZQG","strictid":"SCS03","name":"SCS03","description":"Virus structure and replication in influenza virus, RSV and SARS-CoV-2: latest developments in influenza virus, SARS-CoV-2 and RSV molecular virology ","account_id":"WxRD9M","ts":1607274000},"SPI02":{"id":"AQRkqN","strictid":"SPI02","name":"SPI02","description":"Benefits of vaccination of healthcare workers","account_id":"WxRD9M","ts":1607274000},"SAT01":{"id":"AG1B95","strictid":"SAT01","name":"SAT01 LIVE","description":"Seqirus Satellite Live","account_id":"WxRD9M","ts":1607266800},"PEE01":{"id":"ARXRdy","strictid":"PEE01","name":"PEEK01 LIVE","description":"","account_id":"WxRD9M","ts":1607263200},"KEY01":{"id":"WdEwYe","strictid":"KEY01","name":"KEY01","description":"Barbara Rath","account_id":"WxRD9M","ts":1607259600},"SCS02":{"id":"A0wZO7","strictid":"SCS02","name":"SCS02","description":"Epidemiology, surveillance and modelling of influenza, RSV disease and COVID-19, including virus evolution and strain selection ","account_id":"WxRD9M","ts":1607259600},"SCS01":{"id":"WN4q7v","strictid":"SCS01","name":"SCS01","description":"- viral and host factors in the transmission of influenza, RSV disease and COVID-19 including genomics and big data","account_id":"WxRD9M","ts":1607259600},"KEY07":{"id":"WEzPa4","strictid":"KEY07","name":"KEY07","description":"Zenghli SHI","account_id":"WxRD9M","ts":1607252400},"KEY06":{"id":"VPryB6","strictid":"KEY06","name":"KEY06","description":"Mike Ison","account_id":"WxRD9M","ts":1607252400},"SPI01":{"id":"Wq1Bee","strictid":"SPI01","name":"SPI01 LIVE","description":"How to join forces in influenza pandemic preparedness, what can we learn from COVID-19 stakeholder debate ","account_id":"WxRD9M","ts":1607252400},"OPN01":{"id":"27EaO9","strictid":"OPN01","name":"OPN01 LIVE","description":"Live Opening Ceremony","account_id":"WxRD9M","ts":1607245200}}
clevercast items
{"SCS03":{"id":"VeqK59","strictid":"SCS03","name":"SCS03_MASTER_CLEVERCAST_v01.mp4","description":"","account_id":"WxRD9M","chapters":[]},"KEY09":{"id":"2MLY8z","strictid":"KEY09","name":"KEY09","description":"Keynote Janina Krambach","account_id":"WxRD9M","chapters":[]},"COM03":{"id":"AZgx0j","strictid":"COM03","name":"COM03","description":"Company Keynote Cidara","account_id":"WxRD9M","chapters":[]},"SCS01":{"id":"WooQxg","strictid":"SCS01","name":"SCS01","description":"SCS 01- viral and host factors in the transmission of influenza, RSV disease and COVID-19 including genomics and big data","account_id":"WxRD9M","chapters":[]},"WEB01":{"id":"27jb0Z","strictid":"WEB01","name":"WEB01","description":"WEBINAR 1","account_id":"WxRD9M","chapters":[]},"WEB02":{"id":"WqOjo5","strictid":"WEB02","name":"WEB02","description":"WEBINAR 2","account_id":"WxRD9M","chapters":[]},"WEB03":{"id":"VyQaY9","strictid":"WEB03","name":"WEB03","description":"WEBINAR 3","account_id":"WxRD9M","chapters":[]},"WEB04":{"id":"2b73Dw","strictid":"WEB04","name":"WEB04","description":"Webinar 4","account_id":"WxRD9M","chapters":[]},"SCS02":{"id":"WxQprM","strictid":"SCS02","name":"SCS02","description":"SCS 02- Epidemiology, surveillance and modelling of influenza, RSV disease and COVID-19, including virus evolution and strain selection ","account_id":"WxRD9M","chapters":[]},"SPI07":{"id":"AJ1l01","strictid":"SPI07","name":"SPI07","description":"SPI 07 Burden of influenza, RSV disease and COVID-19 and impact on society","account_id":"WxRD9M","chapters":[{"position":138.679,"name":"Rebecca Cox"},{"position":778.62,"name":"Kathy Leung"},{"position":1431.473,"name":"John Paget"},{"position":2577.432,"name":"Susan C. Bolge"},{"position":3391.09,"name":"Miloje Savic"},{"position":3931.034,"name":"Jojanneke Van Summeren"}]},"SPI03":{"id":"WxQpKX","strictid":"SPI03","name":"SPI03","description":"SPI 03 - why are influenza and RSV a priority for policy makers and what can learn from COVID-19 ","account_id":"WxRD9M","ts":null},"KEY01":{"id":"VvQ67y","strictid":"KEY01","name":"KEY01","description":"Keynote Barbara Rath","account_id":"WxRD9M","ts":null},"KEY05":{"id":"W9j3ME","strictid":"KEY05","name":"KEY05","description":"Keynote Neil Ferguson","account_id":"WxRD9M","ts":null},"KEY07":{"id":"VeqKXQ","strictid":"KEY07","name":"KEY07","description":"Keynote ZHENGLI SHI","account_id":"WxRD9M","ts":null},"KEY04":{"id":"2nO4KR","strictid":"KEY04","name":"KEY04","description":"Keynote Melanie Saville","account_id":"WxRD9M","ts":null}}
Sun 6 Dec
Sunday
6
December

Sunday 6 December, 08:00 - 10:00 CET

Webinar: Influenza and RSV in a COVID-19 world

Time:

Sunday 6 December, 08:00 - 10:00 CET


Chair:
Ab Osterhaus, TiHo, Hannover

  1. Influenza, RSV and COVID-19: similarities and differences
    Arnold Monto,University of Michigan , USA
  2. Epidemiology: what if COVID-19 strikes in the flu season?
    Colin Russell, University of Amsterdam , NL
  3. Challenges in serology for COVID-19
    Linfa Wang, Duke-NUS Medical School , SG
  4. Diagnoses for influenza, RSV and COVID-19 and consequences
    Marco Goeijenbier, Erasmus MC , NL

Sunday 6 December, 10:00 - 12:00 CET

Opening ceremony

Live
Time:

Sunday 6 December, 10:00 - 12:00 CET


Chairs:

Ab Osterhaus, RIZ Hannover, Germany

Marco Goeijenbier, Erasmus MC, The Netherlands

Colin Russell, Academic Medical Center Amsterdam, The Netherlands

Brooke Nichols, Boston University, United States of America


Programme:
  1. ECDC Director Andrea Ammon’s message to participants of the ESWI Influenza Conference

    Andrea Ammon, European Centre for Disease Prevention and Control, Sweden
  2. Opening keynote lecture: The latest on the covid-19 global situation & how the pandemic spread

    Sylvie Briand, World Health Organisation, Switzerland
  3. Opening keynote lecture: Hemagglutinin-stalk based universal influenza virus vaccines

    Florian Krammer, Icahn School of Medicine at Mount Sinia, United States of America

Sunday 6 December, 12:00 - 12:30 CET

Keynote lecture: From SARS to COVID-19, understanding the interspecies transmission of SARS-related coronaviruses

Time:

Sunday 6 December, 12:00 - 12:30 CET

Tracks:

Scientific Programme, Keynote lectures


Speaker:
Zhengli Shi, Wuhan Institute of Virology

Sunday 6 December, 12:00 - 14:00 CET

How to join forces in influenza pandemic preparedness – what can we learn from COVID-19?

Live
Time:

Sunday 6 December, 12:00 - 14:00 CET

Track:

Science Policy Interface


Chair:
Sylvie van der Werf, Institut Pasteur

Programme:
  1. The vaccine R&D ecosystem after COVID-19: paradigm shifts or business as usual in tackling future influenza pandemic threats?

    Marissa D Malchione, Sabin Vaccine Institute, Washington, DC, USA
  2. The Alliance for Influenza Preparedness: strategic priorities to enhance our global response to the next pandemic.

    Joseph Bresee, US CDC, United States of America
  3. The threat of a new influenza pandemic: its certainty, its unpredictability (or not?), its potential magnitude and speed.

    Gülsah Gabriel, Heinrich-Pette-Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany
  4. Challenges in the supply of influenza Vaccines during the COVID-19 Pandemic and lessons learned

    Beverly Taylor, International Federation of Pharmaceutical Manufacturers and Associations, United Kingdom

Sunday 6 December, 14:00 - 14:30 CET

Keynote lecture: A shift in perspective: Understanding the patient experience of Influenza, COVID and RSV

Time:

Sunday 6 December, 14:00 - 14:30 CET

Tracks:

Scientific Programme, Keynote lectures


Speaker:
Barbara Rath, Vienna Vaccine Safety Initiative

Sunday 6 December, 14:00 - 16:00 CET

Viral and host factors in the transmission of influenza, RSV disease and COVID-19, including genomics and big data

Time:

Sunday 6 December, 14:00 - 16:00 CET

Track:

Scientific Programme


Chairs:
Ron Fouchier, Erasmus MC Rotterdam
Maria Auladell, University of Melbourne

Programme:
  1. Influenza viruses with reduced baloxavir susceptibility demonstrate lower fitness in ferrets

    Leo Yi Yang Lee, WHO Collaborating Centre for Reference and Research on Influenza, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
  2. The relationship between viral shedding in nose, throat and exhaled breath and symptom severity of respiratory viruses

    Nancy H. L. Leung, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong
  3. N-glycolylneuraminic acid-binding of H7 Influenza A viruses

    Cindy M. Spruit, Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands
  4. Novel model to determine how influenza viral shedding correlates with infectiousness and to predict the impact of antivirals on reduction of influenza transmission

    Jason Asher, Leidos, Reston, Virginia, USA

Sunday 6 December, 14:00 - 16:00 CET

Epidemiology, surveillance and modeling of influenza, RSV disease and COVID-19, including virus evolution and strain selection

Time:

Sunday 6 December, 14:00 - 16:00 CET

Track:

Scientific Programme


Chairs:
Colin Russell, Academic Medical Center, University of Amsterdam
Bingyi Yang, The University of Hong Kong

Programme:
  1. Mapping the global antigenic diversity of avian H7 influenza A viruses

    Adinda Kok, Department of Viroscience, Postgraduate School Molecular Medicine, Erasmus MC, Rotterdam, The Netherlands
  2. National influenza surveillance systems in five European countries: a comparative framework based on WHO guidance

    Thierry Rigoine de Fougerolles, Corporate Value Associates, France
  3. Evolution of receptor specificity of contemporary A/H3N2 explains inability to agglutinate erythrocytes

    Frederik Broszeit, Utrecht University, The Netherlands
  4. Difference in the age and gender distribution of Covid-19 cases following movement restriction measures in Asia

    Damien Alain Michel Philippon, WHO Collaborating Center for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
  5. Evaluating virus interference in a trial of influenza vaccination in children

    Tim K. Tsang, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.

Sunday 6 December, 15:00 - 16:00 CET

Poster Peek with Marco Goeijenbier

Live
Time:

Sunday 6 December, 15:00 - 16:00 CET


Marco Goeijenbier discusses trending posters.

Sunday 6 December, 16:00 - 18:00 CET

Satellite symposium organised by Seqirus: Strengthening influenza protection: Different needs, different solutions

Live
Time:

Sunday 6 December, 16:00 - 18:00 CET

Track:

Satellite sessions


Chair:
Joan Puig-Barberà, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO)

Programme:
  1. Protecting a diverse population

    Joan Puig-Barberà, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Spain
  2. Safeguarding the older generation

    Caterina Rizzo, Bambino Gesù Pediatric Hospital, Italy
  3. Shielding special populations

    Catherine Moore, Public Health Wales, United Kingdom
  4. Preparing for an influenza pandemic – and what we can learn from SARS-CoV-2

    Florian Krammer, Icahn School of Medicine at Mount Sinia, United States of America
  5. Panel and audience discussion

    Joan Puig-Barberà, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Spain
  6. Closing remarks

    Joan Puig-Barberà, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Spain

Sunday 6 December, 18:00 - 20:00 CET

Special keynote lecture Janssen: Janssen’s efforts in the development of a COVID-19 vaccine

Time:

Sunday 6 December, 18:00 - 20:00 CET

Track:

Keynote lectures


Speaker:
Hanneke Schuitemaker, Janssen

Sunday 6 December, 18:00 - 20:00 CET

Virus structure and replication in influenza virus, RSV and SARS-CoV-2; latest developments in influenza virus, SARS-CoV-2 and RSV molecular virology

Time:

Sunday 6 December, 18:00 - 20:00 CET

Track:

Scientific Programme


Chairs:
Ervin Fodor, University of Oxford
Aitor Nogales, National Institute for Agricultural and Food Research and Technology (INIA)

Programme:
  1. Upstream translation initiation expands the coding capacity of influenza viruses

    Lea Meyer, MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK
  2. Optimized reverse genetics systems for clinical isolates of respiratory syncytial virus enables rapid evaluation of naturally occurring antibody escape mutants

    Alina Schadenhofer, Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Germany
  3. Homologous PB2-HA packaging signals direct influenza A virus reassortment

    Courtney L. Steger, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA
  4. Alternative splicing liberates a cryptic cytoplasmic isoform of mitochondrial MECR that antagonizes influenza virus

    Steven F. Baker, Department of Medical Microbiology and Immunology, University of Wisconsin-Madison, United States of America
  5. Host ANP32A mediates the assembly of the influenza virus replicase

    Haitian Fan, Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, United Kingdom

Sunday 6 December, 18:00 - 20:00 CET

Benefits of vaccination of healthcare workers

Time:

Sunday 6 December, 18:00 - 20:00 CET

Track:

Science Policy Interface


Chair:
Hanna Nohynek, Finnish Institute for Health and Welfare

Programme:
  1. Annual seasonal influenza vaccination of health care workers

    Rebecca Cox, University of Bergen, Norway
  2. Mandatory vaccination for healthcare workers in the US

    Litjen Tan, National Adult Immunization Summit and National Influenza Vaccine Summit, United States of America
  3. Current recommendations and guidelines for healthcare workers vaccination: an overview

    Ted van Essen, General Practice, The Netherlands
  4. The ethics of influenza vaccination of healthcare workers: a critical appraisal

    Sarah Edwards, University College London, United Kingdom

Sunday 6 December, 20:00 - 22:00 CET

Satellite symposium organised by AstraZeneca: Targeting SARS-CoV-2: Novel vaccines and antivirals for the prevention and treatment of COVID-19

Live
Time:

Sunday 6 December, 20:00 - 22:00 CET

Track:

Satellite sessions


PROGRAMME:

Chair’s introduction, Dr Jorge Flores, Global Head, Clinical, PATH Center for Vaccine Innovation and Access, Washington, DC, USA

New advances in COVID-19 vaccine development, Prof. Sarah Gilbert, Jenner Institute, University of Oxford, Oxford, UK

Exploring new therapies for COVID-19: Focus on monoclonal antibodies, Dr Mark Esser, Vice President, Microbial Sciences, R&D BioPharmaceuticals, AstraZeneca, Gaithersburg, MD, USA

Q&A with panel

Veeva ID: Z4-27960

Sunday 6 December, 22:00 - 22:30 CET

Recap of the day: Highlights with Colin Russell and Brooke Nichols

Live
Time:

Sunday 6 December, 22:00 - 22:30 CET


Mon 7 Dec
Monday
7
December

Monday 7 December, 08:00 - 08:30 CET

Morning welcome lecture: Antiviral and Immune Modifiers for Treatment of Influenza, RSV and COVID-19

Time:

Monday 7 December, 08:00 - 08:30 CET

Track:

Keynote lectures


Speaker:
Michael Ison, Northwestern University

Monday 7 December, 08:00 - 10:00 CET

Webinar: Clinical manifestations of Influenza, RSV and COVID-19

Time:

Monday 7 December, 08:00 - 10:00 CET


Chair:
Ab Osterhaus, TiHo, Hannover

  1. Clinical signs and symptoms: overlap and differences 
    Barbara Rath, Vienna Vaccine Safety Initiative, DE
  2. Risk groups: overlap and difference 
    Daniel Feikin, World Health Organisation, CH
  3. Clinical guidelines and symptomatic treatment 
    Peter Openshaw, Imperial College London, UK
  4. Co-Infections: Possible scenario’s
    Bruno Lina, Université de Lyon , FR

Monday 7 December, 09:00 - 09:15 CET

Good morning with Colin Russell

Live
Time:

Monday 7 December, 09:00 - 09:15 CET


Monday 7 December, 10:00 - 12:00 CET

Satellite symposium organised by the Influenza Diabetes Community, supported by Sanofi Pasteur: Influenza in persons living with diabetes. Pathogenesis and prevention

Live
Time:

Monday 7 December, 10:00 - 12:00 CET

Track:

Satellite sessions


Chairs:
Marco Goeijenbier, Erasmus MC
Francesc Xavier Cos, Primary Care Diabetes Europe/ Institut Català de la salut

Programme:
  1. The impact of influenza on people with diabetes

    Marco Goeijenbier, Erasmus MC, The Netherlands
  2. Influenza vaccination and people with diabetes: a must !

    Francesc Xavier Cos, Primary Care Diabetes Europe/ Institut Català de la salut, Spain
  3. Recent findings in glycemic variability and influenza severity

    Kirsty Short, University of Queensland, Australia
  4. How to increase vaccination coverage in people with diabetes, the UK case

    Dan Howarth, Diabetes UK, United Kingdom
  5. Diabetes during the COVID-19 pandemic

    Ab Osterhaus, TiHo, Hannover, Germany

Monday 7 December, 12:00 - 12:30 CET

Special keynote lecture Janssen: Immunology underpinning vaccine strategy in COVID-19

Time:

Monday 7 December, 12:00 - 12:30 CET

Track:

Keynote lectures


Speaker:
Peter Openshaw, Imperial College London

Monday 7 December, 12:00 - 12:30 CET

Keynote lecture: SARS-CoV2 : the hamster infection model, developing antiviral strategies and a unique single dose vaccine based on the yellow fever vaccine

Time:

Monday 7 December, 12:00 - 12:30 CET

Track:

Keynote lectures


Speaker:
Johan Neyts, University of Leuven

Monday 7 December, 12:00 - 13:00 CET

Poster Peek with Brooke Nichols

Live
Time:

Monday 7 December, 12:00 - 13:00 CET


Colin Russell discusses trending posters.

Monday 7 December, 12:00 - 14:00 CET

All you need to know about influenza, RSV disease and COVID-19

Time:

Monday 7 December, 12:00 - 14:00 CET

Track:

Science Policy Interface


Chair:
Ab Osterhaus, TiHo, Hannover

Programme:
  1. Impact of Influenza Vaccination on Antibiotic Use and Antimicrobial Resistance: a Mixed Methods Study to Develop a Strategic Plan

    Lotte van Heuvel, Nivel, Netherlands Institute for Health Services Research, The Netherlands
  2. All you need to know about influenza, both epidemic and pandemic

    Ab Osterhaus, TiHo, Hannover, Germany
  3. All you need to know about RSV disease

    Terho Heikkinen, University of Turku, Finland
  4. COVID-19 Vaccine Development and Approvals in the US: Operation Warp Speed

    Arnold Monto, University of Michigan, United States of America
  5. How viruses travel tricky routes

    Colin Russell, Academic Medical Center, University of Amsterdam, The Netherlands

Monday 7 December, 14:00 - 16:00 CET

Satellite symposium organised by Janssen: Addressing the ever-changing burden of RSV: The past, present and post COVID-19

Live
Time:

Monday 7 December, 14:00 - 16:00 CET

Track:

Satellite sessions


Chair:
Peter Openshaw, Imperial College London

Programme:
  1. Welcome and Introduction

    Peter Openshaw, Imperial College London, United Kingdom
  2. New insights into the full burden of RSV infection in children

    Terho Heikkinen, University of Turku, Finland
  3. Overcoming the identity crisis of RSV in adults: An under-recognised burden in at-risk populations

    Edward Walsh, Rochester General Hospital, United Kingdom
  4. Planning for a post-Covid-19 world: Can we expect large RSV outbreaks in 2021/2022?

    Peter Openshaw, Imperial College London, United Kingdom
  5. Panel Discussion

    Peter Openshaw, Imperial College London, United Kingdom
  6. Meeting close

    Peter Openshaw, Imperial College London, United Kingdom

Monday 7 December, 16:00 - 16:30 CET

Keynote lecture: RNA Structure in Influenza and Coronaviruses: A Comparison

Time:

Monday 7 December, 16:00 - 16:30 CET

Track:

Keynote lectures


Speaker:
David LV Bauer, The Francis Crick Institute

Monday 7 December, 16:00 - 18:00 CET

Viral and host factors in the pathogenesis of influenza, RSV disease and COVID-19, including genomics and big data

Time:

Monday 7 December, 16:00 - 18:00 CET

Track:

Scientific Programme


Chairs:
Barney Graham, Vaccine Research Center, NIAID, NIH
Kirsty Short, University of Queensland

Programme:
  1. Cellular importin-α3 expression dynamics in the lung regulate antiviral response pathways against influenza A virus infection

    Sebastian Beck, Viral Zoonosis – One Health, Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany
  2. Adaptation of an HPAI H5N1 virus to the ferret central nervous system?

    Jurre Y. Siegers, Dept. of Viroscience, Erasmus MC, Rotterdam, the Netherlands
  3. Comparative genomics and transcriptomics help unravel why Australian Black Swans are uniquely susceptible to highly pathogenic avian influenza (HPAI)

    Anjana Karawita, School of Chemistry and Molecular Biosciences, The University of Queensland, Australia; Australian Centre for Disease Preparedness Services, CSIRO, Geelong, Australia
  4. Species-specific endotheliotropism of Highly Pathogenic Avian Influenza Virus in avian hosts

    Anja C.M. de Bruin, Department of Viroscience, Erasmus Postgraduate School Molecular Medicine, Erasmus MC, Rotterdam, The Netherlands
  5. Female-biased vaccine-induced immunity and protection against influenza A viruses is maintained against drifted and viruses in mice

    Rebecca Ursin, Johns Hopkins University Bloomberg School of Public Health, Department of Biochemistry and Molecular Biology, Baltimore, MD, USA

Monday 7 December, 16:00 - 18:00 CET

Reservoirs for future pandemics: threats from the animal world

Live
Time:

Monday 7 December, 16:00 - 18:00 CET

Track:

Scientific Programme


Chairs:
Ab Osterhaus, TiHo, Hannover
Guha Asthagiri Arunkumar, Icahn School of Medicine at Mount Sinai

Programme:
  1. Co-infections with low and high pathogenic avian influenza H5N8 virus demonstrate that HPAIV are more likely to emerge in chickens than in ducks

    Pierre Bessiere, Université de Toulouse, INRAE-ENVT, France
  2. Antigenic characterization of novel H1 influenza A viruses in swine

    Rodrigo Tapia, Departamento de Medicina Preventiva Animal, Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago, Chile.
  3. Characterizing the Functionality of the Wuhan Spiny Eel Influenza Virus Surface Glycoproteins

    Guha Asthagiri Arunkumar, Dept of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  4. Influenza D virus: a potential threat for humans?

    Claudia Trombetta, University of Siena, Italy

Monday 7 December, 16:00 - 18:00 CET

Influenza, RSV disease and COVID-19 intervention strategies: current practice and future strategies

Time:

Monday 7 December, 16:00 - 18:00 CET

Track:

Science Policy Interface


Chair:
Menno de Jong, University of Amsterdam

Programme:
  1. Suppressing COVID-19 transmission in three epidemic waves in Hong Kong

    Peng Wu, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong S.A.R. (China)
  2. Pre-pandemic and pandemic vaccines

    Florian Krammer, Icahn School of Medicine at Mount Sinia, United States of America
  3. Antivirals influenza, RSV, COVID-19: key recent developments

    Frederick Hayden, Professor Emeritus of Medicine, United States of America
  4. Non medical interventions

    Angeliki Melidou, European Centre for Disease Prevention and Control, Sweden
  5. Regulatory requirements of (pre)pandemic vaccines

    Marco Cavaleri, European Medicines Agency, The Netherlands

Monday 7 December, 18:00 - 18:30 CET

Special keynote lecture Cidara Therapeutics: Beyond Vaccines and mAbs: Progress Towards Universal Influenza Protection with Cloudbreak® Influenza Antiviral Conjugates (AVCs)

Time:

Monday 7 December, 18:00 - 18:30 CET

Track:

Keynote lectures



Programme:
  1. Opening remarks

    Michael Grundel Ison, Northwestern University, United States of America
  2. Beyond Vaccines and mAbs: Progress Towards Universal Influenza Protection with Cloudbreak® Influenza Antiviral Conjugates (AVCs)

    Leslie Tari, Cidara Therapeutics, United States of America

Monday 7 December, 18:00 - 18:30 CET

Meet Colin Russell and Marco Goeijenbier in the lounge

Live
Time:

Monday 7 December, 18:00 - 18:30 CET


Monday 7 December, 18:00 - 20:00 CET

Innate and adaptive immune responses in influenza, RSV disease and COVID-19

Time:

Monday 7 December, 18:00 - 20:00 CET

Track:

Scientific Programme


Chairs:
Giuseppe Sautto, University of Georgia
Guus Rimmelzwaan, University of Veterinary Medicine Hannover, Foundation

Programme:
  1. In-concert immune dynamics during natural influenza virus infection and recovery in acute hospitalized patients

    Thi H. O. Nguyen, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville 3010, Victoria, Australia
  2. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses

    LC Rowntree, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; Co-first
  3. Suboptimal SARS-CoV-2-specific CD8+ T-cell response associated with the prominent HLA-A*02:01 phenotype

    Jennifer R Habel, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia
  4. Molecular and functional dissection of the influenza virus-specific CD8+ T cell receptor repertoire during aging

    CE van de Sandt, Dept. Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute, Melbourne, Australia; Dept. Hematopoiesis, Sanquin Blood Supply Foundation, Amsterdam, The NetherlandsSanquin Blood Supply Foundation, Amsterdam, The Netherlands
  5. A history of obesity increases the severity of influenza virus infection and the pro-inflammatory response of pulmonary leukocytes

    Ellesandra C. Noye, School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia Queensland 4072, Australia

Monday 7 December, 18:00 - 20:00 CET

Influenza, RSV disease and COVID-19 from a global health perspective, including underserved communities

Time:

Monday 7 December, 18:00 - 20:00 CET

Track:

Science Policy Interface


Chair:
Marta Nunes, University of the Witwatersrand

Programme:
  1. PEDSIDEA_Community: Real-time Mapping of Influenza/RSV/COVID Incidence & Severity in Underserved Communities in the United States

    Barbara Rath, Vienna Vaccine Safety Initiative, Germany
  2. What is the impact of COVID-19 in underserved communities?

    Olivia Trulloch, Anthrologica, United Kingdom
  3. Unique features of the epidemiology of influenza and COVID-19 in low and middle-income countries – implications for policy

    Cheryl Cohen, University of the Witwatersrand, South Africa
  4. Global access to vaccines for LMIC- challenges and opportunities

    Niteen Wairagkar, Vaccines for All, United States of America

Monday 7 December, 20:00 - 20:30 CET

Recap of the day: Highlights with Colin Russell and Ab Osterhaus

Live
Time:

Monday 7 December, 20:00 - 20:30 CET


Tue 8 Dec
Tuesday
8
December

Tuesday 8 December, 08:00 - 08:30 CET

Morning welcome lecture: Host cell factors that impact the emergence of pandemic respiratory viruses

Time:

Tuesday 8 December, 08:00 - 08:30 CET

Track:

Keynote lectures


Speaker:
Wendy Barclay, Imperial College London

Tuesday 8 December, 08:00 - 10:00 CET

Webinar: Intervention strategies for COVID-19, influenza and RSV

Time:

Tuesday 8 December, 08:00 - 10:00 CET


Chair:
Ab Osterhaus, TiHo, Hannover

  1. Current strategies
    Ab Osterhaus, RIZ, Hannover , Germany 
  2. Testing and testing consequences
    Chantal Reusken, RIVM , The Netherlands
  3. Influenza vaccination during COVID-19
    Florian Krammer, Icahn School of Medicine , USA
  4. Antivirals & Biological Response Modifiers
    Mike Ison, Northwestern University , USA

Tuesday 8 December, 09:00 - 09:15 CET

Good morning with Brooke Nichols

Live
Time:

Tuesday 8 December, 09:00 - 09:15 CET


Tuesday 8 December, 09:00 - 09:30 CET

Meet the expert (sponsored by Roche): Strategies to Reduce Influenza Transmission – limited availability, registration required

Time:

Tuesday 8 December, 09:00 - 09:30 CET

Track:

Keynote lectures


Speakers:
Andreas Widmer, University of Basel
Leo Yi Yang Lee, Peter Doherty Institute for Infection and Immunity

Tuesday 8 December, 10:00 - 10:30 CET

Keynote lecture: COVID-19 vaccine development: where are we?

Time:

Tuesday 8 December, 10:00 - 10:30 CET

Track:

Keynote lectures


Speaker:
Melanie Saville, CEPI

Tuesday 8 December, 10:00 - 12:00 CET

Influenza, RSV disease and COVID-19: clinical impact and diagnostic approaches (including disease management in primary healthcare and hospital settings)

Time:

Tuesday 8 December, 10:00 - 12:00 CET

Track:

Scientific Programme


Chairs:
Marco Goeijenbier, Erasmus MC
Tristan Clark, University of Southampton

Programme:
  1. Clinical Impact of Molecular Point-of-Care Testing for COVID-19 in Adults Presenting to Hospital: A Prospective, Interventional, Non-Randomised, Controlled Study (CoV-19POC)

    Nathan J Brendish, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Department of Infection, University Hospital Southampton NHS Foundation Trust, Southampton, UK
  2. Impact of a routine molecular point-of-care ‘test and treat’ strategy for influenza in hospitalised adults: a multi-centre, randomised controlled trial (FluPOC)

    Tristan W Clark, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Department of Infection, University Hospital Southampton NHS Foundation Trust, Southampton, UK; NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; NIHR Post Doctoral Fellowship Programme, UK
  3. Global Study of Adults Hospitalized with Influenza, Respiratory Syncytial Virus (RSV) and Human Metapneumonvirus (hMPV): Risk Factors, Clinical Characteristics and Outcomes

    Ann Falsey, Rochester General Hospital, University Of Rochester School Of Medicine
  4. Pooled nasal and throat swabs, nasal swabs and saliva as alternative clinical specimens for the diagnosis of COVID-19: a systematic review and meta-analysis

    Ngai Yung Tsang, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR.
  5. Lethal and not-so-lethal mutagenesis: Changes in fitness and mutation rate during the treatment of respiratory syncytial virus with ribavirin and favipiravir

    Chris Illingworth, University of Cambridge, United Kingdom

Tuesday 8 December, 10:00 - 12:00 CET

Young Scientists at work

Live
Time:

Tuesday 8 December, 10:00 - 12:00 CET

Track:

Scientific Programme


Chairs:
Ab Osterhaus, TiHo, Hannover
Gülsah Gabriel, Heinrich Pette Institute

Programme:
  1. Announcement Best Body of Work Award

    Ab Osterhaus, TiHo, Hannover, Germany
  2. Understanding influenza A virus receptor specificity is essential for vaccine development

    Robert de Vries, Utrecht University, The Netherlands
  3. Announcement of the Innovative Award

    Russell Basser, Seqirus, United States of America
  4. Metabolic disease and COVID-19

    Kirsty Short, University of Queensland, Australia
  5. Dynamics of human life-course antibody profiles to influenza A (H3N2)

    Bingyi Yang, The University of Hong Kong, Hong Kong S.A.R. (China)
  6. Influenza virus infection history drives and shapes antibody and B cell responses to seasonal influenza vaccination

    Maria Auladell, University of Melbourne, Australia

Tuesday 8 December, 12:00 - 14:00 CET

Satellite symposium organised by BioNTech: The Road to COVID-19 Vaccine Development

Live
Time:

Tuesday 8 December, 12:00 - 14:00 CET

Track:

Satellite sessions


The Road to COVID-19 Vaccine Development 

Platforms, Clinical Data, and Expert Perspectives 

Objectives: 

  • To discuss how COVID-19 vaccines have been developed at high speed while maintaining rigorous safety and efficacy standards, and how multidisciplinary collaboration has enabled this 
  • To review the current technologies underpinning the potential COVID-19 vaccine frontrunners 
  • To provide a brief overview of the data available to date for the potential COVID-19 vaccines in development 
  • To share expert insights on the future of COVID-19 and what actions will be crucial in a post-pandemic world 

Agenda

12:00 – 12:10    Welcome Address 

12:10 – 12:30    Accelerated Development: How COVID-19 Vaccines are Being Developed Safely in Record Time 

12:30 – 12:50    Platforms to Launch: The Cutting-Edge Technologies Underpinning COVID-19 Vaccines in Development 

12:50 – 1:10      Latest Data and Insights: COVID-19 Vaccine Candidates 

1:10 – 1:25        Panel Q&A 

1:25 – 1:50        Multidisciplinary Discussion 

                          What Happens Next? Approaching Vaccination in a Post-pandemic World 

1:50 – 2:00        Final Summary & Close

Tuesday 8 December, 14:00 - 14:30 CET

Keynote lecture: Long-distance airborne dispersal of SARS-CoV-2 in COVID-19 wards

Time:

Tuesday 8 December, 14:00 - 14:30 CET

Track:

Keynote lectures


Speaker:
Janina Krambrich, Uppsala University

Tuesday 8 December, 14:00 - 15:00 CET

Poster Peek with Colin Russell

Live
Time:

Tuesday 8 December, 14:00 - 15:00 CET


Marco Goeijenbier discusses trending posters.

Tuesday 8 December, 14:00 - 16:00 CET

Threats and risk management of epidemics and pandemics

Time:

Tuesday 8 December, 14:00 - 16:00 CET

Track:

Scientific Programme


Chairs:
Colin Russell, Academic Medical Center, University of Amsterdam
Ann Moen, World Health Organization

Programme:
  1. Avian H5 influenza A viruses: towards antigen design of a universal H5 vaccine

    Mathilde Richard, Department of Viroscience, ErasmusMC, The Netherlands
  2. A meta-analysis on the role of children in SARS-CoV-2 in household transmission clusters

    Yanshan Zhu, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane Australia
  3. Rapid global SARS-CoV-2 external quality assurance (EQA) programme by influenza mechanism of the Global Influenza Surveillance and Response System (GISRS)

    Dmitriy Pereyaslov, World Health Organization, Switzerland
  4. Social contact patterns and age dependent susceptibility shape the re-emergence potential of A/H3N2 influenza viruses

    Joseph Gibson, Amsterdam University Medical Center, The Netherlands

Tuesday 8 December, 14:00 - 16:00 CET

Influenza, RSV disease and COVID-19 vaccination: current and future approaches

Time:

Tuesday 8 December, 14:00 - 16:00 CET

Track:

Scientific Programme


Chairs:
Barney Graham, Vaccine Research Center, NIAID, NIH
Miruna Elena Rosu, Erasmus Medical Center

Programme:
  1. Detailed analysis of the immune response after ChAdOx1 nCOV-19 vaccination

    Teresa Lambe, Jenner Institute, Nuffield Department of Medicine, University of Oxford, United Kingdom
  2. Conserved hemagglutinin stem immunogens elicit cross-group protective broadly neutralizing antibody responses to influenza A viruses

    Syed Moin, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
  3. Potent protective immunity to influenza by HA nanoparticle vaccines

    Seyhan Boyoglu-Barnum, NIH, United States of America
  4. Structure-based design of stabilized recombinant influenza neuraminidase tetramers

    Julia Lederhofer, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States
  5. AS03-adjuvanted recombinant SARS-CoV-2 S antigen vaccine candidate: from non-clinical to clinical development

    Valerie Lecouturier, Sanofi Pasteur, Marcy l'etoile, France

Tuesday 8 December, 14:00 - 16:00 CET

Antiviral and immune therapy for influenza, RSV disease and COVID-19

Time:

Tuesday 8 December, 14:00 - 16:00 CET

Track:

Scientific Programme


Chairs:
Frederick Hayden, Professor Emeritus of Medicine
Joanne Mckenzie, University of Sheffield

Programme:
  1. Combining baloxavir with standard-of-care (SoC) neuraminidase inhibitor (NAI) in patients hospitalised with severe influenza: results from the global randomised phase 3 FLAGSTONE study

    Deepali Kumar, University Health Network, Toronto, Ontario, Canada
  2. Structural and functional characterization of a SARS-CoV-1 and -2 cross-neutralizing single domain antibody and their clinical potential

    Xavier Saelens, Ghent University and VIB, Belgium
  3. Treatment-Emergent Resistance to the Influenza Antiviral Baloxavir: Pooled Analysis of Baloxavir Clinical Trials

    Jinnie Ko, Genentech, Inc., South San Francisco, CA, United States of America
  4. Characterization of In Vitro Activity and In Vivo Efficacy of CD377, a Novel Anti-Viral Fc-Conjugate, Against 2020-2021 Northern Hemisphere Influenza Quadrivalent Vaccine Strains

    Jeffrey Locke, Cidara Therapeutics, United States of America

Tuesday 8 December, 16:00 - 18:00 CET

Satellite symposium organised by Roche: Can we stop flu going viral?

Live
Time:

Tuesday 8 December, 16:00 - 18:00 CET

Track:

Satellite sessions


Chair:
Frederick Hayden, Professor Emeritus of Medicine

Programme:
  1. Welcome and introduction

    Frederick Hayden, Professor Emeritus of Medicine, United States of America
  2. Antiviral treatment in hospitalised patients: Setting the scene

    Frederick Hayden, Professor Emeritus of Medicine, United States of America
  3. Antiviral treatment in hospitalised patients

    Jean-Paul Mira, Centre Hospitalier Paris Centre, France
  4. Role of antiviral treatment in reducing the spread of influenza: Setting the scene

    Frederick Hayden, Professor Emeritus of Medicine, United States of America
  5. Role of antiviral treatment in reducing the spread of influenza

    Lauren Meyers, The University of Texas at Austin, United States of America
  6. Panel discussion with Jean-Paul Mira, Lauren Meyers, Menno de Jong, Deepali Kumar, Benjamin Cowling, Terho Heikkinen

    Frederick Hayden, Professor Emeritus of Medicine, United States of America
  7. Summary and closing remarks

    Frederick Hayden, Professor Emeritus of Medicine, United States of America

Tuesday 8 December, 18:00 - 20:00 CET

Satellite symposium organised by Sanofi Pasteur: 10 years of evidence using high dose influenza vaccine in people age 65 and older

Live
Time:

Tuesday 8 December, 18:00 - 20:00 CET

Track:

Satellite sessions


Chair:
Rosalind Hollingsworth, Sanofi Pasteur

Programme:
  1. Opening remarks

    Rosalind Hollingsworth, Sanofi Pasteur, United States of America
  2. Burden of influenza diseases in people 65 years old and over

    Thomas Weinke, Klinikum Ernst von Bergmann, Germany
  3. High dose influenza vaccine: benefits for older adults

    Marc Van Ranst, University of Leuven, Belgium
  4. North America experience: high dose vaccine focus on long term care

    Stefan Gravenstein, Case Western Reserve University, United States of America
  5. Q&A and Closing Remarks with Thomas Weinke, Marc Van Ranst, Stefan Gravenstein

    Rosalind Hollingsworth, Sanofi Pasteur, United States of America

Tuesday 8 December, 20:00 - 20:30 CET

Meet Colin Russell and Brooke Nichols in the lounge

Live
Time:

Tuesday 8 December, 20:00 - 20:30 CET


Tuesday 8 December, 20:30 - 21:00 CET

Recap of the day: Highlights with Colin Russell and Marco Goeijenbier

Live
Time:

Tuesday 8 December, 20:30 - 21:00 CET


Wed 9 Dec
Wednesday
9
December

Wednesday 9 December, 08:00 - 08:15 CET

Morning welcome lecture: Risk factors for severe outcomes following COVID-19 infection -results of a systematic literature review

Time:

Wednesday 9 December, 08:00 - 08:15 CET

Track:

Keynote lectures


Speaker:
Pasi Penttinen, European Centre for Disease Prevention and Control (ECDC)

Wednesday 9 December, 08:00 - 10:00 CET

Webinar: Cornerstones of pandemic preparedness and urgent actions

Time:

Wednesday 9 December, 08:00 - 10:00 CET


Chair:
Ab Osterhaus, TiHo, Hannover

  1. Vaccination
    Ab Osterhaus, RIZ, Hannover , Germany
    Jonathan Anderson, Seqirus , Australia
  2. Antivirals
    Frederick Hayden, University of Virginia , USA
  3. Non-medical interventions
    Angeliki Melidou, ECDC , Sweden
  4. Cross-sector collaboration and communication
    Sylvie Briand, World Health Organisation , Switzerland

Wednesday 9 December, 09:00 - 09:15 CET

Good morning with Marco Goeijenbier

Live
Time:

Wednesday 9 December, 09:00 - 09:15 CET


Wednesday 9 December, 09:00 - 09:30 CET

Meet the expert (sponsored by Roche): Management of Hospitalised Patients with Severe Influenza – limited availability, registration required

Time:

Wednesday 9 December, 09:00 - 09:30 CET

Track:

Keynote lectures


Speakers:
Tristan Clark, University of Southampton
Jean-Paul Mira, Centre Hospitalier Paris Centre

Wednesday 9 December, 10:00 - 12:00 CET

Satellite symposium organised by ESPID and ESWI. Should we introduce national live vaccination programmes for children?

Live
Time:

Wednesday 9 December, 10:00 - 12:00 CET

Track:

Satellite sessions


Chair:
Terho Heikkinen, University of Turku

AstraZeneca has provided a sponsorship grant towards this independent Programme


Programme:
  1. Why is influenza an important disease in children? An introduction.

    Terho Heikkinen, University of Turku, Finland
  2. Efficacy and safety of seasonal influenza vaccination in children

    Ab Osterhaus, TiHo, Hannover, Germany
  3. The burden of paediatric influenza in the US: mortality, hospitalizations, outpatients visits and other outcome

    Patsy Stinchfield, Children's Hospitals and Clinics of Minnesota, United States of America
  4. How to increase vaccine confidence and counter parental doubts on the safety and effectiveness of influenza vaccines?

    Hanna Nohynek, Finnish Institute for Health and Welfare, Finland
  5. Debate: should we introduce live vaccination programmes for children?

    Terho Heikkinen, University of Turku, Finland

Wednesday 9 December, 12:00 - 12:30 CET

Keynote lecture: Transmission dynamics and control of COVID-19: what have we learned so far?

Time:

Wednesday 9 December, 12:00 - 12:30 CET

Track:

Keynote lectures


Speaker:
Neil Ferguson, Imperial College London

Wednesday 9 December, 12:00 - 13:00 CET

Poster Peek with Colin Russell

Live
Time:

Wednesday 9 December, 12:00 - 13:00 CET


Colin Russell discusses trending posters.

Wednesday 9 December, 12:00 - 14:00 CET

Animal influenza, ecology and epidemiology

Time:

Wednesday 9 December, 12:00 - 14:00 CET

Track:

Scientific Programme


Chairs:
Malik Peiris, The University of Hong Kong
Rodrigo Tapia, Virbac-Centrovet

Programme:
  1. Transmission dynamics of avian influenza viruses along poultry value chains in Bangladesh: a controlled field experiment

    Lisa Kohnle, City University of Hong Kong, Hong Kong S.A.R. (China)
  2. In vivo and in vitro characterization of highly pathogenic influenza A virus (H5N8) neurotropism in duck and chicken.

    Thomas Figueroa, Université de Toulouse, ENVT, INRAE, UMR 1225, Toulouse, France
  3. Sentinel Birds as an Indicator of the Influenza Virus Presence in the Natural Environment

    Semen Tkachenko, National Scientific Center Institute of Experimental and Clinical Veterinary Medicine
  4. LPAIV Prevalence, Subtype Diversity and Migration Connectivity of Dabbling Duck the Azov-Black Sea Region in Ukraine

    Denys Muzyka, National Scientific Center Institute of Experimental and Clinical Veterinary Medicine, Kharkiv, Ukraine
  5. Case Report - A case comparison of early versus late detection and depopulation of two chicken farms infected with highly pathogenic avian influenza virus during the 2015 H5N2 outbreak

    Kaitlyn St. Charles, Secure Food Systems Team, University of Minnesota, College of Veterinary Medicine, United States of America

Wednesday 9 December, 12:00 - 14:00 CET

Influenza, RSV disease and COVID-19 vaccination: current and future approaches

Time:

Wednesday 9 December, 12:00 - 14:00 CET

Track:

Scientific Programme


Chairs:
Peter Openshaw, Imperial College London
Dennis Lapuente, University Hospital Erlangen

Programme:
  1. Contribution of neuraminidase to the efficacy of seasonal split influenza vaccines in the ferret model

    Miruna E. Rosu, Department of Viroscience, Erasmus Medical Center, Rotterdam 3015 CE, the Netherlands
  2. Antigen modifications improve mRNA-based influenza virus vaccine efficacy in mice

    Alec W Freyn, Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029
  3. IL-1β as mucosal vaccine adjuvant: Specific induction of tissue-resident memory T cells and enhanced protection against heterologous IAV

    Dennis Lapuente, Institute of Clinical and Molecular Virology, University Hospital Erlangen, Germany
  4. A comprehensive influenza reporter virus panel for decomposing polyclonal sera using neutralization maps

    Adrian Creanga, National Institute of Allergy and Infectious Diseases, United States of America
  5. CELL RESPONSE 2: Relative vaccine effectiveness against influenza-related hospitalizations and serious respiratory events during the 2018/19 influenza season in children and adults. Comparison between quadrivalent cell-based and egg-based influenza vaccines

    Joaquin Federico Mould-Quevedo, Seqirus Vaccines Ltd., Summit, NJ, USA

Wednesday 9 December, 14:00 - 14:30 CET

Keynote lecture

Time:

Wednesday 9 December, 14:00 - 14:30 CET

Track:

Keynote lectures


Speaker:
Heidi Larson, London School of Hygiene & Tropical Medicine

Wednesday 9 December, 14:00 - 16:00 CET

Co-infections in influenza, RSV disease and COVID-19

Time:

Wednesday 9 December, 14:00 - 16:00 CET

Track:

Scientific Programme


Chair:
Ed Hutchinson, University of Glasgow

Programme:
  1. The burden and clinical characteristics of viral respiratory disease before and during the SARS-CoV-2 pandemic

    Stephen Poole, NIHR Biomedical Research Centre Southampton, United Kingdom; University Hospitals Southampton NHS Trust
  2. Evolution and selection of influenza a virus defective interfering particles in a semi-continuous production system for the use as antiviral

    Lars Pelz, Max-Planck Institute for Dynamics of Complex Technical Systems, Germany
  3. Superinfection exclusion limits genome interactions during localised spread of influenza A viruses.

    Anna Sims, MRC-University of Glasgow Centre for Virus Research, United Kingdom
  4. Aspergillosis Complicating Severe Influenza and Respiratory Syncytial Virus (RSV) in ICU Patients

    Hannah Hyochan Nam, University of California, Irvine, United States of America

Wednesday 9 December, 14:00 - 16:00 CET

Risk evaluation and communication strategies in influenza and COVID-19: lessons learned

Time:

Wednesday 9 December, 14:00 - 16:00 CET

Track:

Science Policy Interface


Chair:
Pasi Penttinen, European Centre for Disease Prevention and Control (ECDC)

Programme:
  1. Cross-sectoral collaboration and communication

    Tim Nguyen, World Health Organisation, Switzerland
  2. The role of experts in guiding policy

    Peter Openshaw, Imperial College London, United Kingdom
  3. Reaching out to people at risk – focus on the elderly: why and how,

    Janet McElhaney, Northern Ontario School of Med, United States of America
  4. Talking vaccines is risky business: challenges in the post-trust environment

    Frederic Bouder, University of Stavanger, Norway

Wednesday 9 December, 14:00 - 16:00 CET

Burden of influenza, RSV disease and COVID-19 and impact on society

Time:

Wednesday 9 December, 14:00 - 16:00 CET

Track:

Science Policy Interface


Chairs:
Rebecca Cox, University of Bergen
Kathy Sze Man Leung, The University of Hong Kong

Programme:
  1. Mortality Associated with Seasonal Influenza Epidemics in the European Union: Overall Estimates based on Respiratory Mortality from 2002-2011

    John Paget, Nivel, Utrecht, the Netherlands
  2. Excess Mortality and Healthcare Resource Use Attributed to Influenza in People at High Risk for Developing Complications: Real World Evidence from a US Managed Care Population

    Susan C. Bolge, Janssen Global Services, LLC, Raritan, USA
  3. A Systematic Literature Review and a Meta-analysis of the Respiratory Syncytial Virus (RSV) Burden of Disease in Adults Over 60 Years of Age

    Miloje Savic, GSK, Wavre, Belgium
  4. The disease burden of respiratory syncytial virus infection in young children in primary care: results from the RSV ComNet pilot in Italy and the Netherlands

    Jojanneke JGT van Summeren, Nivel, Netherlands Institute for Health Services Research, Utrecht, Netherlands, The

Wednesday 9 December, 16:00 - 18:00 CET

Late Breakers: novel and outstanding scientific discoveries

Live
Time:

Wednesday 9 December, 16:00 - 18:00 CET

Track:

Scientific Programme


Chair:
Mariette Ducatez, INRAE

Programme:
  1. The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways

    Manon Laporte, KU Leuven, Rega Institute for Medical Research, Belgium
  2. The avian-to-human adaptation of the 1968 A/H3N2 pandemic influenza virus

    Zandra Felix Garza, Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  3. Phase 1 trial Results of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants and Adjuvanted with GSK’s Pandemic Adjuvant

    Brian J. Ward, Medicago Inc., Canada; Research Institute of the McGill University Health Centre, Canada
  4. The contrasting within-host evolutionary dynamics between seasonal and pandemic human influenza A viruses

    Alvin X. Han, Laboratory of Applied Evolutionary Biology, Department of Medical Microbiology, Amsterdam University Medical Center, Amsterdam, The Netherlands1Laboratory of Applied Evolutionary Biology, Department of Medical Microbiology, Amsterdam University Medical Center, Amsterdam, The Netherlands
  5. Acute, Suprapharmacologic Dexamethasone Mobilizes Natural Killer T and Cytotoxic T cells for Influenza A/B-induced or COVID-19-induced ARDS

    Theresa Deisher, AVM Biotechnology, United States of America

Wednesday 9 December, 18:00 - 18:15 CET

Recap of the day: Highlights with Colin Russell, Marco Goeijenbier and Brooke Nichols

Live
Time:

Wednesday 9 December, 18:00 - 18:15 CET


Wednesday 9 December, 18:15 - 19:00 CET

Closing ceremony

Live
Time:

Wednesday 9 December, 18:15 - 19:00 CET


  FILTER